CABAZITAXEL | N201023 | SANOFI AVENTIS US INC
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2016-00712 | 8927592 | IPR | Mylan Laboratories Limited et al. | Final Written Decision | 2016-03-15 | — |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2022-01-31 | Terminated 2022-04-29 | — | |
| D. Del. | 2020-11-17 | Terminated 2021-01-25 | — | |
Sanofi-Aventis U.S. LLC, et al. v. Sandoz Inc. 2 patentsANDA 207736, 207619, 207718, 207591cabazitaxel | D. Del. | 2020-06-12 | Terminated 2023-07-05 | — |
| D. Del. | 2020-06-12 | Terminated 2020-08-06 | — | |
| D. Del. | 2020-06-05 | Terminated 2021-09-08 | — | |
| D. Del. | 2020-05-14 | Terminated 2020-08-11 | — | |
| D.N.J. | 2015-01-14 | Terminated 2017-09-26 | — | |
SANOFI-AVENTIS U.S. LLC et al v. BRECKENRIDGE PHARMACEUTICAL, INC. 2 patentsANDA 207619cabazitaxel | D.N.J. | 2015-01-14 | Terminated 2018-03-05 | — |
| D.N.J. | 2014-12-17 | Terminated 2018-03-05 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Anne A. Shirinian-Orlando FDA-2018-P-2749 · 4 docket documents Anne A. Shirinian-Orlando filed this petition under Section 355(e) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA issue strict dosage and administration guidelines for prostate cancer chemotherapy medications including Zytiga (abiraterone acetate), Jevtana (cabazitaxel), and Xta | Other | 2018-07-18 | Open | Anne A. Shirinian-Orlando |
Source: Regulations.gov. FDA citizen petitions matched by application number.